BV
Elite in Leiomyosarcoma

Dr. Brian A. Van Tine

Siteman Cancer Center
Saint Louis, MO
Elite
 in Leiomyosarcoma
Specialties:Oncology
Experience:18 Years
Clinical Trials:Currently Recruiting for 19 Trials
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Brian A. Van Tine's experience treating your condition:
About Dr. Brian A. Van Tine

Brian Van Tine is an Oncologist in Saint Louis, Missouri. Van Tine has been practicing medicine for over 18 years and is rated as an Elite expert by MediFind in the treatment of Leiomyosarcoma. He is also highly rated in 38 other conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, Epithelioid Sarcoma, and Vertebroplasty. He is licensed to treat patients in Missouri. Van Tine is currently accepting new patients.

His clinical research consists of co-authoring 121 peer reviewed articles and participating in 74 clinical trials in the past 15 years. In particular, he has co-authored 10 articles and participated in 6 clinical trials in the study of Leiomyosarcoma.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Brian A. Van Tine it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
4921 Parkview Pl, Saint Louis, MO 63110
Background & Education
Graduate Institution
University Of Alabama School Of Medicine, 2005
Specialties
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Barnes-Jewish Hospital
Barnes-Jewish St Peters Hospital
Barnes-Jewish West County Hospital
Ste Genevieve County Memorial Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

67 Clinical Trials
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma
Enrollment Status: Recruiting
Publish Date: November 21, 2022
Intervention Type: Drug, Other
Study Drugs: UnesbulinDacarbazine
Study Phase: Phase 2/Phase 3
A Phase 1B Study of Unesbulin (PTC596) in Combination With Dacarbazine in Patients With Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma
Enrollment Status: Recruiting
Publish Date: June 30, 2022
Intervention Type: Drug
Study Drugs: PTC596Dacarbazine
Study Phase: Phase 1
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Nivolumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Enrollment Status: Recruiting
Publish Date: August 24, 2022
Intervention Type: Genetic
Study Phase: Phase 1
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes
Enrollment Status: Recruiting
Publish Date: December 07, 2022
Intervention Type: Drug
Study Drug: Nab-sirolimus
Study Phase: Phase 2
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Enrollment Status: Recruiting
Publish Date: April 12, 2022
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Recruiting
Publish Date: November 09, 2022
Intervention Type: Procedure, Drug
Study Drug: Rogaratinib
Study Phase: Phase 2
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
Enrollment Status: Recruiting
Publish Date: August 24, 2022
Intervention Type: Genetic
Study Phase: Phase 2
Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Drug
Study Drugs: PLX3397Sirolimus
Study Phase: Phase 1/Phase 2
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: December 01, 2022
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
Phase 1B/2 Study Of Liposomal Annamycin (L-Annamycin) In Subjects With Previously Treated Soft-Tissue Sarcomas With Pulmonary Metastases
Enrollment Status: Recruiting
Publish Date: August 18, 2022
Intervention Type: Drug
Study Drug: Liposomal Annamycin
Study Phase: Phase 1/Phase 2
Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
Enrollment Status: Recruiting
Publish Date: September 01, 2022
Intervention Type: Drug
Study Drugs: GSK3901961GSK3845097FludarabineCyclophosphamide
Study Phase: Phase 1
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Enrollment Status: Recruiting
Publish Date: December 13, 2022
Intervention Type: Procedure, Biological, Drug
Study Drugs: AtezolizumabBevacizumab
Study Phase: Phase 2
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Recruiting
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Enrollment Status: Recruiting
Publish Date: July 13, 2022
Intervention Type: Other, Drug
Study Drugs: CabozantinibTemozolomide
Study Phase: Phase 2
A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 12, 2022
Intervention Type: Drug
Study Drug: APG-115+Pembrolizumab
Study Phase: Phase 1/Phase 2
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Enrollment Status: Recruiting
Publish Date: May 13, 2022
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Enrollment Status: Recruiting
Publish Date: December 09, 2022
Intervention Type: Genetic
Study Phase: Phase 2
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Enrollment Status: Recruiting
Publish Date: August 25, 2022
Intervention Type: Drug
Study Drugs: SeclidemstatCyclophosphamideTopotecan
Study Phase: Phase 1
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Enrollment Status: Recruiting
Publish Date: December 09, 2022
Intervention Type: Drug
Study Drugs: RamucirumabCyclophosphamideVinorelbine
Study Phase: Phase 1/Phase 2
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 07, 2022
Intervention Type: Procedure, Drug
Study Drugs: Pegylated arginine deiminaseGemcitabineDocetaxel
Study Phase: Phase 2
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Enrollment Status: Active, not recruiting
Publish Date: September 09, 2022
Intervention Type: Drug, Radiation
Study Drug: MDM2 Inhibitor KRT-232
Study Phase: Phase 1
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Enrollment Status: Completed
Publish Date: August 05, 2020
Intervention Type: Drug
Study Phase: Phase 2
PROactive Evaluation of Function to Avoid CardioToxicity
Enrollment Status: Active, not recruiting
Publish Date: June 13, 2022
Intervention Type: Device
Study Phase: Phase 2
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
Enrollment Status: Active, not recruiting
Publish Date: October 19, 2022
Intervention Type: Other, Biological
Study Drugs: IpilimumabNivolumab
Study Phase: Phase 2
A Trial of Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
Enrollment Status: Active, not recruiting
Publish Date: October 18, 2022
Intervention Type: Radiation, Procedure
Study Phase: Not Applicable
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Enrollment Status: Active, not recruiting
Publish Date: August 10, 2022
Intervention Type: Genetic, Radiation
Study Drug: Autologous Genetically Modified MAGE-A4c1032 T-Cells
Study Phase: Phase 1
A Phase I/II Clinical Trial of Dose-Escalating DHEA in Synovial Sarcoma Patients
Enrollment Status: Terminated
Publish Date: September 09, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: OlaratumabGemcitabineDocetaxel
Study Phase: Phase 1/Phase 2
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Enrollment Status: Not yet recruiting
Publish Date: November 15, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Active, not recruiting
Publish Date: December 07, 2021
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase I Trial of Lattice Stereotactic Body Radiation Therapy (Lattice SBRT) for Localized Unresectable or Metastatic Conventional Type Chondrosarcoma
Enrollment Status: Withdrawn
Publish Date: September 16, 2020
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
Enrollment Status: Active, not recruiting
Publish Date: August 18, 2021
Intervention Type: Drug
Study Drug: Efatutazone
Study Phase: Phase 2
Tumor Ablation in Metastatic Sarcoma Stable on Chemotherapy
Enrollment Status: Terminated
Publish Date: September 19, 2018
Intervention Type: Other, Device
Study Phase: Phase 2
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 30, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Active, not recruiting
Publish Date: October 20, 2022
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: January 11, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active, not recruiting
Publish Date: November 18, 2022
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: AvapritinibRegorafenib
Study Phase: Phase 3
A Pilot Study of NY-ESO-1c259T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma
Enrollment Status: Completed
Publish Date: November 28, 2022
Intervention Type: Drug
Study Drugs: Letetresgene autoleucelCyclophosphamideFludarabine
Study Phase: Phase 2
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Enrollment Status: Suspended
Publish Date: November 25, 2022
Intervention Type: Drug
Study Drugs: RamucirumabGemcitabineDocetaxel
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1
Enrollment Status: Terminated
Publish Date: July 07, 2020
Intervention Type: Biological
Study Phase: Phase 2
Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma
Enrollment Status: Completed
Publish Date: February 13, 2017
Intervention Type: Drug
Study Phase: Phase 2
A Trial of Palliative Lattice Stereotactic Body Radiotherapy (SBRT)
Enrollment Status: Completed
Publish Date: November 22, 2021
Intervention Type: Radiation, Procedure
Study Phase: Not Applicable
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Enrollment Status: Active, not recruiting
Publish Date: October 26, 2021
Intervention Type: Drug
Study Drug: Enzalutamide
Study Phase: Phase 2
A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) With Pazopanib (P) or Gemcitabine (G) With Docetaxel (T) in Previously Treated Subjects With Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: April 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Participants Following First Line Systemic Anti-cancer Therapy (V943-003, IMDZ-04-1702)
Enrollment Status: Terminated
Publish Date: April 16, 2020
Intervention Type: Biological, Other
Study Phase: Phase 3
A 2-part Trial Comparing Overall Survival of Patients With Metastatic Ewing's Sarcoma Treated With Vigil Versus Gemcitabine and Docetaxel and to Determine Safety Profile of Vigil in Combination With Irinotecan and Temozolomide.
Enrollment Status: Completed
Publish Date: July 22, 2022
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Enrollment Status: Active, not recruiting
Publish Date: April 20, 2022
Intervention Type: Drug
Study Drugs: DexrazoxaneDoxorubicin
Study Phase: Phase 2
A Pilot Study of 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
Enrollment Status: Withdrawn
Publish Date: December 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Active, not recruiting
Publish Date: November 03, 2022
Intervention Type: Drug
Study Drugs: AnlotinibDecarbazine
Study Phase: Phase 3
View 31 Less Clinical Trials -
121 Total Publications
Are the Pieces Starting to Come Together for Management of Desmoid Tumors?
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 10, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
PT
Dr. Premal H. Thaker
Gynecologic Oncology | Oncology
Distinguished
Highly rated in
25
conditions
Gynecologic Oncology
Oncology

BJC HealthCare

Washington University

Saint Louis, MO 

Premal Thaker is a Gynecologic Oncologist and an Oncologist in Saint Louis, Missouri. Thaker has been practicing medicine for over 26 years and is rated as an Elite expert by MediFind in the treatment of Leiomyosarcoma. She is also highly rated in 25 other conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Hysterectomy, and Oophorectomy. She is licensed to treat patients in Missouri. Thaker is currently accepting new patients.

PO
Dr. Peter J. Oppelt
Oncology
Distinguished
Highly rated in
49
conditions
Oncology

BJC HealthCare

Division Of Oncology

150 Entrance Way, 
St. Peters, MO 
 20.2 mi

Peter Oppelt is an Oncologist in St. Peters, Missouri. Oppelt has been practicing medicine for over 15 years and is rated as a Distinguished expert by MediFind in the treatment of Leiomyosarcoma. He is also highly rated in 49 other conditions, according to our data. His top areas of expertise are Tongue Cancer, Adult Soft Tissue Sarcoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and Fibrosarcoma. He is licensed to treat patients in Missouri. Oppelt is currently accepting new patients.

JP
Dr. Joel Picus
Oncology
Distinguished
Highly rated in
17
conditions
Oncology

BJC HealthCare

Department Of Radiation Oncology

5225 Mid America Plz, 
Saint Louis, MO 
 12.0 mi

Joel Picus is an Oncologist in Saint Louis, Missouri. Picus has been practicing medicine for over 39 years and is rated as a Distinguished expert by MediFind in the treatment of Leiomyosarcoma. He is also highly rated in 17 other conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Chromophobe Renal Cell Carcinoma, Bladder Cancer, and Orchiectomy. He is licensed to treat patients in Missouri. Picus is currently accepting new patients.